10-Year Free Cash Flow Projections(showing years 1, 3, 5, 7, 10)
| Year | Year 1 | Year 3 | Year 5 | Year 7 | Year 10 |
|---|
| Revenue | $345.9B | $395.7B | $481.6B | $566.8B | $647.9B |
| EBIT | $3.2B | $3.7B | $4.5B | $44.2B | $89.1B |
| Tax | $968M | $1.1B | $1.3B | $13.3B | $26.7B |
| NOPAT | $2.3B | $2.6B | $3.1B | $30.9B | $62.4B |
| + Depreciation | $571M | $654M | $795M | $936M | $1.1B |
| - Capex | $549M | $628M | $764M | $899M | $1.0B |
| - Δ NWC | $2.5B | $2.6B | $4.7B | $4.1B | $1.9B |
| Free Cash Flow | -$179M | -$7M | -$1.5B | $26.9B | $60.5B |
| Discount Factor | 0.937 | 0.824 | 0.724 | 0.636 | 0.524 |
| Present Value | -$168M | -$6M | -$1.1B | $17.1B | $31.7B |
FCF Formula: Free Cash Flow = NOPAT + Depreciation - Capex - Change in Net Working Capital
Sensitivity AnalysisPrice per Share
| WACC ↓ / Growth → | 2.00% | 2.50% | 3.00% | 3.50% | 4.00% |
|---|
| 4.67% | $7,940.79 | $8,835.12 | $8,969.35 | $8,578.57 | $8,206.54 |
| 5.67% | $6,288.47 | $6,697.24 | $7,259.15 | $8,080.13 | $8,206.54 |
| 6.67% | $5,240.05 | $5,464.37 | $5,749.84 | $6,125.39 | $6,641.63 |
| 7.67% | $4,489.61 | $4,626.62 | $4,792.98 | $4,999.24 | $5,261.71 |
| 8.67% | $3,913.02 | $4,002.82 | $4,108.46 | $4,234.53 | $4,387.61 |
How to read: This table shows how the valuation changes with different WACC (discount rate) and terminal growth rate assumptions. Green = undervalued, Red = overvalued.
Key Assumptions & Drivers✓ Using Analyst Consensus Estimates• Healthcare Sector
Growth Assumptions (Select Years)
Year 1 Revenue Growth7.66%
Year 3 Revenue Growth7.08%
Year 5 Revenue Growth10.84%
Year 7 Revenue Growth7.70%
Year 10 Revenue Growth3.00%
Terminal Growth Rate3.00%
Margin & Efficiency
Current EBIT Margin0.93%
Terminal EBIT Margin20.00%
Tax Rate30.00%
Historical Capex / Rev0.16%
NWC / Revenue10.00%
Key Drivers: Revenue growth, operating margin expansion, capex efficiency, and working capital management are the primary drivers of cash flow generation. Terminal value assumptions significantly impact final valuation.
Institutional-Grade Methodology
Actual Company Data: Revenue, EBIT, Capex, NWC, Tax Rate, Interest Expense, Beta
Market Assumptions: Risk-free: 4.5% (10Y), MRP: 4.5% (Damodaran 2026), Exit: 24x EV/EBITDA (Healthcare sector)
This DCF model is for informational purposes only. Projections are based on assumptions that may not materialize. Past performance does not guarantee future results. Consult a financial advisor before making investment decisions.